Genentech Issues Dear Healthcare Provider Letter Regarding A 2nd Case Of PML In A Raptiva Patient Genentech, Inc. (NYSE: DNA) announced that the company has issued a Dear
Healthcare Provider letter to inform dermatologists and neurologists of a 2nd case of progressive multifocal leukoencephalopathy (PML) which resulted in the death of a 73-year old woman who had received Raptiva® (efalizumab) for approximately four years for treatment of chronic plaque psoriasis.
Source: www.medicalnewstoday.comCeregene Announces Clinical Data From Phase 2 Clinical Trial Of CERE-120 For Parkinson's Disease Ceregene, Inc., a biopharmaceutical company, reported clinical data from a double-blind, controlled Phase 2 trial of CERE-120 in 58 patients with advanced Parkinson's disease. The trial did not demonstrate an appreciable difference between patients treated with CERE-120 versus those in the control group.
Source: www.medicalnewstoday.comFDA Issues Complete Response Letter For Ceftobiprole For Treatment Of Complicated Skin Infections Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced that it received a Complete Response letter from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ceftobiprole for the treatment of complicated skin and skin structure infections, including diabetic foot infections. The FDA has indicated that they cannot approve the NDA for ceftobiprole at this time.
Source: www.medicalnewstoday.comSandoz Receives Positive EU Opinion For Biosimilar Filgrastim Sandoz has received a positive opinion from European regulators for its third biosimilar
medicine, filgrastim, marking another important milestone in its efforts to bring affordable high-quality biopharmaceuticals to patients worldwide. Filgrastim is indicated for use in treating neutropenia, a condition characterized by lack of neutrophils - one of the most common types of white blood cells - that is often associated with chemotherapy or bone marrow transplants.
Source: www.medicalnewstoday.com
# posted by Network @ 4:00 AM
